We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Viropro and Invitrogen Signs R&D Collaboration Agreement
News

Viropro and Invitrogen Signs R&D Collaboration Agreement

Viropro and Invitrogen Signs R&D Collaboration Agreement
News

Viropro and Invitrogen Signs R&D Collaboration Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Viropro and Invitrogen Signs R&D Collaboration Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Viropro Inc. and Invitrogen Corp. have entered into an R&D collaboration in which Invitrogen is testing and helping to develop production technologies.

Viropro's protein production expertise combined with Invitrogen PD Direct™'s media and cell line development expertise will yield new solutions for pharmaceutical and biotech companies.

This collaboration would represent recurring revenues and royalties for Viropro following integration of the technology with Invitrogen PD Direct™'s customized media platforms.

Additionally, Viropro has an opportunity to out-license the technology and sign intellectual property (IP) agreements with other major biotech companies interested in integrating novel IP into their research and manufacturing processes.

“The fact that an industry leader like Invitrogen has shown a concrete interest in our technology is a clear sign of Viropro's ability to choose innovative and cutting edge intellectual property for the realization of our business model,” said Viropro CEO, Jean-Marie Dupuy.

Jeff Greenberg, VP of BioProduction of Invitrogen stated that, “We are enthusiastic about testing this new technology and hope to establish a long-term relationship with Viropro.”

Advertisement